Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 6Phase 3 5Phase 1 2

Status

Completed 10Active not recruiting 5Not yet recruiting 3Terminated 2Recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 4Tumor-Agnostic 1

Conditions

Stomach Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma 1Advanced Colorectal Cancer 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Carboplatin 106Cisplatin 97Paclitaxel 78pembrolizumab 69Gemcitabine 59Pemetrexed 49Cyclophosphamide 46Docetaxel 45Dexamethasone 45durvalumab 44Capecitabine 44Radiotherapy 40Nivolumab 37Lenalidomide 37Specimen Handling 36Doxorubicin 36Rituximab 34Oxaliplatin 34Bevacizumab 33Magnetic Resonance Spectroscopy 32Fluorouracil 32atezolizumab 29Etoposide 29Vincristine 26Radiation 26Leucovorin 26Letrozole 24Bortezomib 24Fulvestrant 23Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × trifluridine tipiracil drug combination × Clear all
NCT06614192 2026-05-28

A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

AbbVie

Phase 3 Active not recruiting
74 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06346392 2026-05-27

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

AstraZeneca

Phase 3 Active not recruiting
592 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06356311 2026-02-27

TroFuse-015

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
450 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT04879368 2025-07-17

INTEGRATEIIb

Australasian Gastro-Intestinal Trials Group

Phase 3 Active not recruiting
450 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT06199973 2025-07-17

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Active not recruiting
130 enrolled
Gastrointestinal

Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡